Need Help?
Announcements
15 May 2024
Cardiogenetics | Aims and Scope Update
To further enhance the quality of Cardiogenetics and the papers published in it, under the guidance of our Editor-in-Chief, Dr. Giuseppe Limongelli, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below:
Scope (new version): |
Scope (old version): |
As an essential resource to general physicians, cardiologists, and geneticists, Cardiogenetics’ primary purpose is to report original research in the following areas: - Clinical and molecular aspects of inherited heart diseases (IHDs): genotype–phenotype findings; follow-up data from IHD clinics; clinical findings from large and informative families with IHDs; studies on molecular imaging in IHDs; - Clinical and molecular aspects of rare diseases: clinical imaging and molecular findings of rare diseases (RDs) with cardiovascular involvement; - Pharmacogenetics and pharmacogenomics: studies involving new drugs or well-known therapies in IHDs, RDs, and cardiovascular medicine; genetic/genomic profile and response to therapies; - Stem cell studies: clinical trials and experimental studies involving cell studies/cell therapy; - Diagnostic methods, including sequencing studies; - Bioinformatics and statistical methods in genetics; - Personalized medicine and therapies (gene therapy and gene editing); - Molecular biology and pathophysiology of genetic and genomic diseases: biology of cells; pathways and systems; epigenetics and gene regulation; biology and pathophysiology of specific genes and non-coding DNA; - Polygenic/multifactorial disorders; -Cellular electrophysiological studies related to inherited arrhythmogenic conditions; -Imaging in cardiogenetics; -Mutation reports. A space will be given to negative studies in cardiogenetics: this space will be dedicated to clinical, molecular, cellular, and pharmacological studies with a solid scientific background that lead to negative results. |
As an essential resource to general physicians, cardiologists, and geneticists, Cardiogenetics’ primary purpose is to report original research in the following areas: - Clinical and molecular aspects of inherited heart diseases (IHDs): genotype–phenotype findings; follow-up data from IHD clinics; clinical findings from large and informative families with IHDs; studies on molecular imaging in IHDs; - Clinical and molecular aspects of rare diseases: clinical imaging and molecular findings of rare diseases (RDs) with cardiovascular involvement; - Pharmacogenetics and pharmacogenomics: studies involving new drugs or well-known therapies in IHDs, RDs, and cardiovascular medicine; genetic/genomic profile and response to therapies; - Stem cell studies: clinical trials and experimental studies involving cell studies/cell therapy; - Diagnostic methods, including sequencing studies; - Bioinformatics and statistical methods in genetics; - Personalized medicine and therapies (gene therapy and gene editing); - Molecular biology and pathophysiology of genetic and genomic diseases: biology of cells; pathways and systems; epigenetics and gene regulation; biology and pathophysiology of specific genes and non-coding DNA; - Polygenic/multifactorial disorders. A space will be given to negative studies in cardiogenetics: this space will be dedicated to clinical, molecular, cellular, and pharmacological studies with a solid scientific background, but leading to negative results. |
For more detailed information, please visit the following link: https://www.mdpi.com/journal/cardiogenetics/about.
Cardiogenetics Editorial Office